Navigation Links
Hyperion Therapeutics Secures $40 Million In Series B Round

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire/ -- Hyperion Therapeutics, a biopharmaceutical company focused on the development and commercialization of gastrointestinal and hepatology therapies for the treatment of Urea Cycle Disorders (UCD) and Hepatic Encephalopathy (HE), today announced a $40 million Series B financing. Leading the round was Sofinnova Ventures, with equal commitments by Highland Capital Partners and NEA, all of Menlo Park, CA. WRF Capital of Seattle, WA also participated.

(Logo: )

"We are pleased with the investors' confidence in Hyperion and our team," said Chris Rivera, President and CEO of Hyperion. "The funding will allow us to complete the licensing deal with Medicis Pharmaceutical Corporation (see press release dated August 28, 2007), build out our management team, advance our clinical trials in UCD and HE, and begin the U.S. promotion of the only two FDA-approved compounds for the treatment of UCD, AMMONUL(R) (sodium phenylacetate and sodium benzoate) Injection 10%/10% and BUPHENYL(R) (sodium phenylbutyrate). We look forward to making an immediate impact on patients through efforts to increase the diagnosis, awareness and treatment of UCD with these life-saving drugs."

"The unmet medical need for patients with Urea Cycle Disorders and Hepatic Encephalopathy remain significant," said James Healy, MD, Ph.D, and General Partner of Sofinnova Ventures. "Hyperion is committed to improving the treatment options for these patients."

In response to the announcement of Hyperion's collaboration with Medicis Pharmaceutical Corporation, Cynthia Le Mons, Executive Director of the National Urea Cycle Disorders Foundation commented, "We are excited about the attention and focus the Hyperion team will bring to increasing UCD diagnosis and improving patients' treatment options. We look forward to working in partnership with Hyperion on shared goals to improve the lives of UCD patients and their families."

Hyperion recently announced their strategic collaboration with Medicis (NYSE: MRX) through which the Company will immediately begin promotion of the only currently FDA approved drugs for the treatment of UCD (AMMONUL and BUPHENYL) and continue developing AMMONUL for acute hepatic encephalopathy (HE) and a compound referred to as GT4P for chronic UCD and HE.

In addition to the Series B financing, Hyperion named the following board members: James Healy of Sofinnova Ventures, Mike Raab of NEA, Bijan Salehizadeh of Highland Capital Partners, and Don Santel, former CEO of CoTherix, Inc.

About Hyperion Therapeutics

Hyperion Therapeutics is a specialty therapeutics company focused on becoming a global leader in gastrointestinal (GI) and hepatology therapeutic programs and products that address underserved patient populations or unmet medical needs to improve patient care. The company has assembled a seasoned executive team with extensive industry experience developing and commercializing specialty pharmaceutical products. Hyperion is headquartered in South San Francisco, CA. For additional information, visit:

AMMONUL and BUPHENYL are registered trademarks of Ucyclyd Pharma, Inc.

Full prescribing information for AMMONUL(R) and BUPHENYL(R) are available at and, respectively, or by contacting Hyperion Therapeutics, Inc.

SOURCE Hyperion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund
3. Perscitus Biosciences secures $250K Commerce loan
4. ProCertus BioPharm secures $2.3M in financing
5. Mirus Bio secures $900K grant to develop research tool
6. BioSystem Development secures angel funding
7. TrafficCast secures $1 million line of credit
8. Medical College secures $9.7M research grant
9. Wausau start up secures $560K for GPS maps
10. Platypus Technologies secures $450K SBIR grant
11. nPoint Secures Second Round of Funding
Post Your Comments:
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):